Outcome of the Financials in the Board Meeting

Profit growth above 25%EBITDA margin expansionDebt to equity above the thresholdResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+14.0%Reaction day

₹42.10

prior close

₹44.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+13.5% vs market

Pharmaceuticals peers, median of 148sector+0.4%+13.6% vs sector

On the reaction day the stock moved 13.5 pts more than Nifty Microcap 250 and 13.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+13.5

10m

+13.5

15m

+13.5

30m

+13.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+14.0+0.6+13.5+0.4+13.6

Next day

+8.5+0.5+8.0+0.3+8.1

+21.1+0.8+20.3+0.5+20.6

+18.8+1.2+17.6+1.0+17.8

+18.8+1.5+17.3+0.6+18.2

+14.6+1.6+13.1-0.1+14.7

+15.9+1.8+14.1+0.1+15.8

15d

+15.9+3.3+12.6+1.5+14.4

+17.7+3.1+14.6-1.2+18.9

+56.8+2.3+54.5+0.6+56.2

-13.1+0.2-13.4-1.6-11.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board of Kimia Biosciences approved the audited financial results for Q4 and FY ended March 31, 2025, with an unmodified audit opinion. The company posted a profit after tax of Rs. 961.24 lakhs in FY25, compared to a loss of Rs. 530.87 lakhs in FY24, driven by a strong swing in pre-tax profit from a Rs. 718.37 lakh loss to a Rs. 1,363.42 lakh profit. Revenue from operations grew about 13.4% to Rs. 11,892.08 lakhs (from Rs. 10,487.65 lakhs), while total expenses fell to Rs. 10,660.69 lakhs from Rs. 11,370.20 lakhs, reflecting better operating efficiency. Total equity strengthened sharply from Rs. 33.10 lakhs to Rs. 996.61 lakhs. The company also began redeeming its preference shares, and non-current borrowings were cut nearly in half.

Likely market impact

This is a clear turnaround story — shareholders should view the return to profitability and improved equity base as positive, though the stock still carries elevated debt (roughly Rs. 32.6 crore in borrowings against ~Rs. 10 crore of equity, a D/E near 3.3x), which remains a watchpoint.